De farmakokinetiske data tyder på, at tilstrækkelige gennemsnitlige palivizumab niveauer blev opnået hos alle 18 børn som deltog.
In an open label prospective trial designed to evaluate pharmacokinetics, safety and immunogenicity after administration of 7 doses of palivizumab within a single RSV season, pharmacokinetic data indicated that adequate mean palivizumab levels were achieved in all 18 children enrolled.